Clinical Trial Update: Donor Stem Cell Transplant in Treating Patients With High-Risk Hematologic Malignancies [Phase 2]

View source ↗

Summary

Phase 2 study evaluating donor stem cell transplantation for high-risk hematologic malignancies has completed and posted results in 2018.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hematologic Malignancies

Snippet

Sponsor: Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | Conditions: Hematologic Malignancy | Phase 2 | Status: COMPLETED | Results posted: 2018-03-16